Mechanistically, SPP1+ TAMs interact with cancer-associated fibroblasts (CAFs) at the invasive margins via SPP1–integrin/CD44 signaling, driving CAF activation, ECM deposition, and chemokine release, which establishes a stromal barrier that excludes CD8+ T cells and promotes ICB resistance. The gene discussed is SPP1; the disease is cancer.